Patricia M McGowan

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. ncbi ADAM-17: a novel therapeutic target for triple negative breast cancer
    P M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 24:362-9. 2013
  2. ncbi Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer
    Patricia M McGowan
    Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
    Mol Cancer Res 9:834-44. 2011
  3. ncbi Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
  4. ncbi Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches
    Patricia M McGowan
    Department Medical Biophysics, University of Western Ontario, London, ON, Canada
    Future Oncol 5:1083-98. 2009
  5. ncbi The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
  6. ncbi Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
  7. ncbi ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
  8. ncbi The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009

Detail Information

Publications8

  1. ncbi ADAM-17: a novel therapeutic target for triple negative breast cancer
    P M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Ann Oncol 24:362-9. 2013
    ..e., those with triple-negative (TN) disease]. ADAM-17 is a protease involved in the activations of several ligands that bind to and promotes intracellular signalling from the EGFR/HER family of receptors...
  2. ncbi Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer
    Patricia M McGowan
    Department of Medical Biophysics, University of Western Ontario, London, Ontario, Canada
    Mol Cancer Res 9:834-44. 2011
    ..001; Kruskal-Wallis). These data suggest that the CSC phenotype contributes to the development of brain metastases from breast cancer, and this may arise in part from increased Notch activity...
  3. ncbi Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
    ..The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha...
  4. ncbi Micrometastatic disease and metastatic outgrowth: clinical issues and experimental approaches
    Patricia M McGowan
    Department Medical Biophysics, University of Western Ontario, London, ON, Canada
    Future Oncol 5:1083-98. 2009
    ..Elucidation of the molecular pathways involved in dormancy will advance clinical understanding and may suggest new avenues for treatment to inhibit the revival of these dormant cells, thereby reducing cancer mortality rates...
  5. ncbi The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
    ..Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer...
  6. ncbi Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
    ..The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy...
  7. ncbi ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
    ..524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression...
  8. ncbi The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009
    ..Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma...